Mikhail V. Pogorelyy
No ORCID on file
· 1 paper in corpus
· active 2021
Frequent coauthors
2021
Current chimeric antigen receptor-modified (CAR) T cell therapy products are evaluated in bulk, without assessment of the possible heterogeneity in effector potential between cells. Conceivably, only a subset of the pre-infusion product dif…